Mar 13, 2023 / 01:20PM GMT
Hartaj Singh - Oppenheimer & Co. Inc., Research Division - Research Analyst
Thank you for joining us. I always have to remember to give that pause. Always thankful to the operators for making this so smooth. Our early morning on a busy and a little bit interesting week here on Wall Street, we've got Regeneron, one of our favorite companies joining us.
We have Neil Stahl and Jamie from there, and Ryan also joining the 3 of them. We'll do a modified sort of fireside chat where we'll talk about the company's pipeline and some of the thoughts as to how the company is pursuing current projects and future projects also. One other Regeneron person was not able to join us, John, but hopefully, later on today, sending him our very best thoughts.
So Ryan, please take it away, and then we'll go to the fireside chat.
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Thanks, Hartaj. I'll try and keep this brief and thanks for hosting us here at the Oppenheimer Healthcare Conference. Just wanted to remind folks that remarks made today may include
Regeneron Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot